Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults

Completed · Phase 1/Phase 2

Conditions studied: Aging

In brief

The purpose of this study is to determine whether treatment of healthy older men and women with oral MK-677 for 12 months will enhance pulsatile GH release and increase mean GH and IGF-I concentrations into the range of young adults and will have favorable effects on body composition and functional ability on older adults.

Key facts

Study ID

NCT00474279

Run by

University of Virginia

People needed

72

Starts

1998-07-01

Expected to finish

2004-06-01

Last updated by the study team

2007-05-16

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy men and women  60 years of age, with a body mass index of < 35 kg/m2.

You may not qualify if…

• Medication known to affect GH secretion, other than estrogen replacement therapy
• Coronary artery disease,
• Congestive heart failure,
• Peripheral vascular disease,
• Diabetes mellitus (requiring insulin or an oral hypoglycemic agent),
• Significant hypertension (BP >180 systolic or >100 diastolic at rest);
• Renal, hepatic, pulmonary disease;
• Untreated hypothyroidism, untreated hyperthyroidism;
• History of seizure disorder;
• History of malignancy (other than some skin cancers), history of active chronic infections (e.g., HIV, tuberculosis).
• Hematocrit < 40%, men, < 36%, women
• History of daily tobacco use within past 3 months
• Chronic alcohol abuse
• Strenuous exercise for average of more than 60 min/day
• Investigational drug within past 6 weeks
• Psychiatric history, especially anorexia nervosa
• Transmeridian travel within 2 weeks prior to or during study

Where it is running

• University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.